期刊
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
卷 172, 期 2, 页码 158-168出版社
WILEY-BLACKWELL
DOI: 10.1111/cei.12052
关键词
cellular therapy; transplantation; Tregs
类别
资金
- National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust
- King's College London
- Medical Research Council (MRC)
- MRC [G0801537, G0600698, G1002000] Funding Source: UKRI
- British Heart Foundation [RG/13/12/30395] Funding Source: researchfish
- Medical Research Council [MR/K025538/1, G0600698, G1002000, G0801537, MR/J006742/1] Funding Source: researchfish
Transplantation is a successful treatment for end-stage organ failure. Despite improvements in short-term outcome, long-term survival remains suboptimal because of the morbidity and mortality associated with long-term use of immunosuppression. There is, therefore, a pressing need to devise protocols that induce tolerance in order to minimize or completely withdraw immunosuppression in transplant recipients. In this review we will discuss how regulatory T cells (Tregs) came to be recognized as an attractive way to promote transplantation tolerance. We will summarize the preclinical data, supporting the importance of these cells in the induction and maintenance of immune tolerance and that provide the rationale for the isolation and expansion of these cells for cellular therapy. We will also describe the data from the first clinical trials, using Tregs to inhibit graft-versus-host disease (GVHD) after haematopoietic stem cell transplantation and will address both the challenges and opportunities in human Treg cell therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据